lewis-x-antigen has been researched along with Seminoma* in 2 studies
2 other study(ies) available for lewis-x-antigen and Seminoma
Article | Year |
---|---|
High endothelial venule-like vessels and lymphocyte recruitment in testicular seminoma.
Seminoma, the most common testicular malignant neoplasm, originates from germ cells and is characterized by the presence of numerous tumour-infiltrating lymphocytes (TILs). Although it is widely accepted that TILs function in surveillance and cytotoxicity in various tumours including seminoma, detailed mechanisms governing TIL recruitment are not fully understood. It has been shown that high endothelial venule (HEV)-like vessels are induced in inflamed and neoplastic tissues and contribute to lymphocyte recruitment in a manner similar to the way physiological lymphocyte homing occurs in secondary lymphoid organs. Here, we report that HEV-like vessels, which express MECA-79(+) 6-sulfo sialyl Lewis X-capped structures, are induced in TIL aggregates in seminoma, and that such vessels potentially recruit circulating lymphocytes, as an E-selectin•IgM chimera bound these vessels in a calcium-dependent manner. These HEV-like vessels express intercellular adhesion molecule 1 (ICAM-1), but not vascular cell adhesion molecule 1 (VCAM-1) or mucosal addressin cell adhesion molecule 1 (MAdCAM-1), which likely contributes to lymphocyte firm attachment. We also found that the number of T cells attached to the luminal surface of HEV-like vessels was greater than the number of B cells (p < 0.0001). Interestingly, while CD8(+) cytotoxic T lymphocytes (CTLs) attached to the lumen of HEV-like vessels were scarcely detected, significant numbers of proliferative CTLs were observed outside vessels. These histological findings strongly suggest that TILs, particularly T cells, are recruited to seminoma tissues via HEV-like vessels, and that tumour-infiltrating CTLs then undergo proliferation after transmigration through HEV-like vessels in testicular seminoma. Topics: Adult; Antigens, CD20; Antigens, Surface; B-Lymphocytes; CD3 Complex; CD79 Antigens; Cell Adhesion Molecules; Cell Proliferation; Endothelium, Vascular; Humans; Immunoglobulins; Intercellular Adhesion Molecule-1; Lewis X Antigen; Lymphocyte Activation; Lymphocyte Count; Lymphocytes, Tumor-Infiltrating; Male; Membrane Proteins; Middle Aged; Mucoproteins; Oligosaccharides; Seminoma; Sialyl Lewis X Antigen; T-Lymphocytes, Cytotoxic; Testicular Neoplasms; Testis; Vascular Cell Adhesion Molecule-1; Venules | 2014 |
Expression of DNA toposiomerase I and DNA topoisomerase II-alpha in testicular seminomas.
DNA topoisomerase I (topo I) is the molecular target of the camptothecin group of anticancer drugs. These drugs are S-phase specific and require elevated topo I for tumor cell killing. To determine whether increased topo I expression occurs in testicular seminomas, 20 cases of testicular seminoma were retrieved from the surgical pathology files at the University of Utah Health Sciences Center and stained with an antibody that recognizes topo I in paraffin embedded human tissue sections. Topo I elevation was observed in 30% (6/20) of the seminomas. Because the response to topo I targeted drugs requires cell proliferation, the proliferative index of the seminomas was determined by immunohistochemical staining for DNA topoisomerase II-alpha (topo II-alpha) a new marker of cell proliferation. AU seminomas had easily detectable topo II-alpha. The average topo II-alpha index of the 20 cases was 52.1 +/- 15.3. Seminomas with elevated topo I had an average topo II-alpha proliferative index of 60.8 +/- 17.5 and seminomas with normal topo I expression had a topo II-alpha proliferative index of 48.4 +/- 13.2. This is significantly different at the 0.05% confidence level. Focal expression of CD30 was seen in 60% (12/20) of the neoplasms. None of the cases showed positive staining for CD15 and c-erbB-2. Our results suggest that chemotherapeutic protocols involving topoisomerase targeting drugs might be useful against testicular seminomas. Topics: Adult; Cell Division; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Humans; Immunohistochemistry; Ki-1 Antigen; Lewis X Antigen; Male; Middle Aged; Receptor, ErbB-2; Seminoma; Testicular Neoplasms | 2000 |